公开(公告)号：US20230149394A1

公开(公告)日：2023-05-18

申请号：US18155483

申请日：2023-01-17

申请人： Amgen Inc. ,  Cytokinetics, Inc.

发明人： Narimon HONARPOUR ,  Fady Malik

IPC分类号： A61K31/496 ,  A61P9/04 ,  A61K9/00

CPC分类号： A61K31/496 ,  A61P9/04 ,  A61K9/0053

摘要： Provided herein are methods of treating a subject with heart failure, comprising administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, and subsequently administering to the subject a dose of the CSA based on the subject's plasma concentration of the CSA at the end of the initial time period.

公开(公告)号：US20230355615A1

公开(公告)日：2023-11-09

申请号：US18313267

申请日：2023-05-05

申请人： Amgen Inc. ,  Cytokinetics, Inc.

发明人： Narimon HONARPOUR ,  Fady MALIK

IPC分类号： A61K31/496 ,  A61K9/00 ,  A61P9/04

CPC分类号： A61K31/496 ,  A61K9/0053 ,  A61P9/04

摘要： Provided herein are methods of treating a subject with heart failure, comprising administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, and subsequently administering to the subject a dose of the CSA based on the subject's plasma concentration of the CSA at the end of the initial time period.

公开(公告)号：US20200368350A1

公开(公告)日：2020-11-26

申请号：US16348653

申请日：2017-11-13

申请人： Amgen Inc.

发明人： Ransi Mudalinayake SOMARATNE ,  Robert Andrew Donald SCOTT ,  Scott WASSERMAN ,  Narimon HONARPOUR ,  Stephen NICHOLLS

IPC分类号： A61K39/395 ,  A61K31/40 ,  A61K31/505 ,  A61K31/366 ,  A61K31/235 ,  A61K31/405 ,  A61K31/47 ,  A61P9/10

摘要： Provided herein are combinations of therapies that provide for the treatment, including regression, of atherosclerosis and/or improvement of cardiovascular outcomes. Generally described, this includes a first, non-PCSK9 LDL-C lowering agent (such as a statin or other non-PCSK9 LDL-C lowering therapy), combined with a second, PCSK9 inhibitor therapy (such as a PCSK9 antibody or anti-RNA). The application of both therapies, at adequately elevated levels so as to reduce the LDL-C level of the subject to very low levels, for an adequate period of time, has been determined to provide an added benefit of further protection from atherosclerosis and improve a subject's cardiovascular outcomes.